RhoVac

News

Shares in Swedish biotech RhoVac were down 94% in mid-morning trading today after the company revealed a phase 2b trial of its prostate

News

There may be a fairly buoyant operating environment for biotechs in the US, but Adecto and Aviceda are winding down, while Caribou is in peril.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.